GSK Acquires Nuvalent for $10.6B in Precision Lung Cancer Bet

GSK announced a $10.6 billion acquisition of Nuvalent, securing two next-generation targeted lung cancer drugs: zidesamtinib (ROS1/ALK inhibitor with CNS penetration) and neladalkib (next-gen ALK inhibitor designed to overcome lorlatinib resistance). The deal represents major consolidation in the precision oncology space, reflecting surging demand for ROS1- and ALK-targeted therapies. Zidesamtinib is in Phase 3 trials for ROS1-positive NSCLC; neladalkib targets a significant unmet need in ALK-positive NSCLC patients who progress on first- and second-generation ALKi. The acquisition underscores how pharma giants are racing to capture the next wave of targeted kinase inhibitors as earlier-generation drugs face resistance.